A Phase 1, Open-Label Study to Evaluate the Pharmacodynamics, Safety and Tolerability of GMI-1271 With and Without Filgrastim in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 27 Apr 2017
At a glance
- Drugs Uproleselan-sodium (Primary) ; Filgrastim
- Indications Stem cell mobilisation
- Focus Pharmacodynamics; Proof of concept
- Sponsors GlycoMimetics
- 30 Jun 2016 Planned number of patients changed from 42 to 54.
- 30 Jun 2016 Status changed from active, no longer recruiting to recruiting.
- 08 Mar 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.